Publication:
Interleukin-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemic

dc.contributor.authorIbarra-Meneses, Ana Victoria
dc.contributor.authorCarrillo, Eugenia
dc.contributor.authorSánchez, C
dc.contributor.authorGarcía-Martínez, J
dc.contributor.authorLópez Lacomba, D
dc.contributor.authorSan Martín, Juan Víctor
dc.contributor.authorAlves, F
dc.contributor.authorAlvar, Jorge
dc.contributor.authorMoreno, Javier
dc.contributor.funderDepartment for International Development (Reino Unido)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderRETICS-Investigación colaborativa en Enfermedades Tropicales (RICET-ISCIII) (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.date.accessioned2020-06-08T07:39:07Z
dc.date.available2020-06-08T07:39:07Z
dc.date.issued2016-08
dc.description.abstractNo field method exists for identifying asymptomatic individuals in areas where Leishmania infantum is endemic. This work reports that, 24 h after stimulating whole blood with soluble Leishmania antigen (SLA), plasma interferon-γ (IFN-γ) and interleukin-2 (IL-2) become significantly elevated in samples from asymptomatic individuals (n=47) compared with those from negative controls (n=50), all of them recruited from a blood bank. When compared with the reference test SLA-lymphoproliferative assay, IL-2 appears as a new, 100% sensitive and specific marker for asymptomatic individuals with a positive cellular response (compared with 100% and 84.78%, respectively, for IFN-γ). Further studies in other transmission areas and in other cohorts of exposed people need to be performed to confirm these results. Once validated, IFN-γ and IL-2 levels in SLA-stimulated whole blood could be reliably used in the field to estimate the prevalence of those asymptomatic individuals with Leishmania-specific cellular immune responses.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipWe gratefully acknowledge the financial support of the Drugs for Neglected Diseases Initiative (DNDi) by the Department for International Development (DFID) , UK and the Swiss Agency for Development and Cooperation (SDC) , Swizerland; and of the Instituto de Salud Carlos III via the Tropical Diseases Research Network ( RICET RD12/0018/ 0003 and RD12/0018/0008 ) (www.ricet.es) and via the ISCIII-AES project ‘ Impact of a leishmaniasis outbreak in the southwest of Madrid in the immunosuppressed population ’ ( PI13/00440 ). EC was supported by a research contract funded via VII PN I+D+I 2013-2016 and FEDER Funds ( RICET RD12/ 0018/0003 ).es_ES
dc.format.number8es_ES
dc.format.page739.e1-4es_ES
dc.format.volume22es_ES
dc.identifier.citationClin Microbiol Infect . 2016 Aug;22(8):739.e1-4es_ES
dc.identifier.doi10.1016/j.cmi.2016.05.021es_ES
dc.identifier.e-issn1469-0691es_ES
dc.identifier.journalClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseaseses_ES
dc.identifier.pubmedID27265372es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10287
dc.language.isoenges_ES
dc.publisherElsevier
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0018/ 0003es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0018/0008es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI13/00440es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0018/0003es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.cmi.2016.05.021es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAsymptomatic Diseaseses_ES
dc.subject.meshLeishmania infantumes_ES
dc.subject.meshAdultes_ES
dc.subject.meshBiomarkerses_ES
dc.subject.meshCytokineses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshInterleukin-2es_ES
dc.subject.meshLeishmaniasis, Viscerales_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshYoung Adultes_ES
dc.titleInterleukin-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemices_ES
dc.typeresearch articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationcf71e409-5422-4199-9853-f56c0cdc3e79
relation.isAuthorOfPublicationbb8f1dfe-8a72-4881-a19f-0b83b988f1bb
relation.isAuthorOfPublicationfaf025ec-ca8d-4d79-a19d-d37e62308551
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublication.latestForDiscoverycf71e409-5422-4199-9853-f56c0cdc3e79
relation.isFunderOfPublication2e6d61b3-462f-4f78-9eff-6faa1496dd6b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication838f52a6-4764-4f63-b87d-fc0e4b0033ee
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication.latestForDiscovery2e6d61b3-462f-4f78-9eff-6faa1496dd6b
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Interleukin2AsA_2016.pdf
Size:
390.47 KB
Format:
Adobe Portable Document Format
Description: